Pyrrole
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- Pyrrole
- Molecular weight
- 67.09
- Structure (SMILES)
- c1cc[nH]c1
- 1h pyrrole
- 1h pyrrole mi
- 1h-pyrrole
- 1H-PYRROLE [MI]
- azole
- Azole
- divinylenimine
- Divinylenimine
- fema no 3386
- FEMA NO. 3386
- imidole
- Imidole
- nsc 62777
- NSC-62777
- pyrrole
- Pyrrole
- PYRROLE [FCC]
- PYRROLE [FHFI]
- PYRROLE [HSDB]
- pyrrole fcc
- pyrrole fhfi
- pyrrole hsdb
- CAS registry numbers
- 109-97-7
- ChEMBL ID
- CHEMBL16225
- InChIKey
- KAESVJOAVNADME-UHFFFAOYSA-N
- PubChem compound IDs
- 8027
- RxNorm IDs (RxCUI)
- 1338938
- FDA ingredient codes (UNII)
- 86S1ZD6L2C
- First in class
- No
- Orphan designation
- No
Investigated indications
- Condition
- Aspergillosis
- Highest recorded phase
- 3
- Condition identifier
- EFO:0007157
- Subject identifier
- D001228
- Condition identifier
- DOID_10113
- Condition identifier
- EFO_0001073
- Condition identifier
- EFO_0007157
- Highest recorded phase
- 3
- Condition identifier
- EFO_1001282
- Condition identifier
- HP_0001513
- Highest recorded phase
- 0
- Condition identifier
- MONDO_0002026
- Condition identifier
- MONDO_0002026
- Highest recorded phase
- 0
- Condition identifier
- MONDO_0002041
- Condition identifier
- MONDO_0006014
- Condition identifier
- MONDO_0011122
- Highest recorded phase
- 0
Trial references
- NCT04876716
- Hydrogen bond acceptors
- 0
- Hydrogen bond donors
- 1
- Polar surface area
- 15.79
- Calculated partition coefficient (ALogP)
- 1.01
- Calculated partition coefficient (XLogP)
- 0.7
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 0
- Heavy atoms
- 5
- Molecular formula
- C4H5N
- Monoisotopic mass
- 67.042199164
- Natural product
- Yes
- Recorded assays
- 461
- Active assays
- 3
Active assay types
- Other
Related records
Trials (2)
- A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- Azole-echinocandin Combination Therapy for Invasive Aspergillosis
In development for (3)
- Aspergillosis Phase 3
- Candidiasis
- Obesity disorder
Other linked conditions (3)
- Fungal infectious disease
- Trypanosomiasis
- Vulvovaginal candidiasis